Simple Summary Peritoneal metastases from gastric cancer have a poor prognosis. Their
presence usually indicates the end-stage of the disease without curative treatment …

Simple Summary Advanced gastric cancer (GCa) is associated with poor prognosis due to
the challenge of peritoneal disease, the most common site of metastasis at initial diagnosis …

Introduction: Treatment of Peritoneal Surface Malignancies (PSM) with cytoreductive surgery
(CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has achieved results never …

Introduction: The role of surgery in stage IV gastric cancer with peritoneal metastasis (PM)
remains unclear. The objective of the current single-center study was to define the impact of …

Simple Summary Peritoneal metastases (PMs), arising from gastric cancer (GC), are one of
the most common patterns of synchronous and metachronous dissemination and are …

Methods: A review of the Library of Congress, the Cochrane Review, Google Scholar,
PubMed, and ClinicalTrials. gov was performed. All articles and trials with available data in …

With the recent negative studies of hyperthermic intraperitoneal chemotherapy (HIPEC) in
colorectal cancer, HIPEC may seem to be up against the ropes in terms of clinical efficacy …

Intraperitoneal chemotherapy for primary gastric cancer - PMC Back to Top Skip to main content
NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main …

Simple Summary Peritoneal disease in gastric cancer has a poor prognosis, with a median
survival of 3–6 months and a 5-year survival rate of 0%. Despite multiple advancements in …

Background: Advances in cytoreductive surgery (CRS) combined with hyperthermic
intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol …